A
Alexander Brawanski
Researcher at University of Regensburg
Publications - 234
Citations - 7765
Alexander Brawanski is an academic researcher from University of Regensburg. The author has contributed to research in topics: Subarachnoid hemorrhage & Cerebral blood flow. The author has an hindex of 43, co-authored 232 publications receiving 7022 citations. Previous affiliations of Alexander Brawanski include University of Würzburg & University Hospital Regensburg.
Papers
More filters
Journal ArticleDOI
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Dagmar Beier,Peter Hau,Martin Proescholdt,Annette Lohmeier,Jörg Wischhusen,Peter J. Oefner,Ludwig Aigner,Alexander Brawanski,Ulrich Bogdahn,Christoph P. Beier +9 more
TL;DR: Together, the data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas, with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo.
Journal ArticleDOI
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Dagmar Beier,Stefanie Röhrl,Deepu R. Pillai,Stefanie Schwarz,Leoni A. Kunz-Schughart,Petra Leukel,Martin Proescholdt,Alexander Brawanski,Ulrich Bogdahn,Ariane Trampe-Kieslich,Bernd Giebel,Jörg Wischhusen,Guido Reifenberger,Peter Hau,Christoph P. Beier +14 more
TL;DR: The data strongly suggest that optimized temozolomide-based chemotherapeutic protocols might substantially improve the elimination of GBM stem cells and consequently prolong the survival of patients.
Journal ArticleDOI
Moderate hypothermia in patients with severe head injury: cerebral and extracerebral effects
C. Metz,Matthias Holzschuh,Thomas Bein,Christian Woertgen,Anton Frey,Irmgard Frey,Kai Taeger,Alexander Brawanski +7 more
TL;DR: Moderate hypothermia is effective in preventing secondary brain damage while reducing cerebral ischemia, however, there are potentially hazardous side effects that require additional monitoring.
Journal ArticleDOI
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.
Peter Hau,Piotr Jachimczak,Reimar Schlingensiepen,Frank J. Schulmeyer,Tanya Jauch,Andreas Steinbrecher,Alexander Brawanski,Martin Proescholdt,J. Schlaier,Johanna Buchroithner,Josef Pichler,Gabriele Wurm,Maximilian Mehdorn,Rainer Strege,Gerhard Schuierer,Victoria Villarrubia,Franz A. Fellner,Olav Jansen,Thorsten Straube,Virinder Nohria,Michael Goldbrunner,Mechthild Kunst,S. Schmaus,Gerhard Stauder,Ulrich Bogdahn,Karl-Hermann Schlingensiepen +25 more
TL;DR: Results implicate targeted TGF-beta2-suppression using AP 12009 as a promising novel approach for malignant gliomas and other highly aggressive, T GF-beta-2-overexpressing tumors.
Journal ArticleDOI
Comparison of serial S-100 and NSE serum measurements after severe head injury.
TL;DR: The results show that the first serum concentration of S-100 seems to be predictive for outcome after severe head injury, and the NSE serum levels did not correlate with intracranial pressure values.